{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:44:59Z","timestamp":1783647899464,"version":"3.55.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background\u2003Pulmonary metastases in papillary thyroid carcinoma have two common presentations\u2014micro\/miliary (MM) and macronodular metastases (MN). The mainstay of treatment, posttotal thyroidectomy, is multiple radioactive iodine ablations (RAIA) every 6 to 12 months. Response assessment is determined by decline in stimulated serum thyroglobulin levels (sTg), disease regression on chest x-ray (CXR), computed tomography thorax, or whole body iodine scintigraphy (TWBS).<\/jats:p>\n                  <jats:p>Aim\u2003This study aims to assess the difference in response to RAIA based on the pattern of presentation.<\/jats:p>\n                  <jats:p>Methodology\u2003Retrospective analysis of patients from January 2008 to July 2017 was done. Patients with pulmonary metastases treated with RAIA (3700MBq per therapy as opposed to theAmerican Thyroid Association recommendation of 7400MBq per therapy) and a minimum follow-up of 8 months were included. The initial and the final sTg, TWBS, and CXR were analyzed for both groups. Final outcome in terms of complete response, disease regression, static disease, and disease progression was determined.<\/jats:p>\n                  <jats:p>Results\u2003Of the total of 1,793 patients, 71 were included. There were 43 females and 28 males. The median age was 39 years and the range was 14 to 79 years. Forty-five (63.3%) patients had MM and 26 (36.6%) patients had MN disease. The average number of therapies was three and maximum follow-up period was 15 years. Of the 45\u2009MM patients, 1 had progression, 7 were static, 23 had regression, and 14 had complete response. Of the 26 MN patients, 22 had progression, 2 were static, 1 had regression, and 1 had complete response.<\/jats:p>\n                  <jats:p>Conclusion\u2003MM metastases, when compared with MN disease, respond to RAIA with a better outcome. In addition to achieving comparable response with a lower dose per therapy, there were no radiation-related long-term complications reported.<\/jats:p>","DOI":"10.1055\/s-0042-1746175","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T18:30:18Z","timestamp":1651343418000},"page":"052-058","source":"Crossref","is-referenced-by-count":5,"title":["Treatment Response following Radioactive Iodine Therapy in Miliary versus Macronodular Pulmonary Metastases in Papillary Thyroid Carcinoma"],"prefix":"10.1055","volume":"21","author":[{"given":"S. S.","family":"Sunny","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hephzibah","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Shanthly","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Oommen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Cherian","sequence":"additional","affiliation":[{"name":"Department of Endocrine Surgery, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"issue":"05","key":"ref1","first-page":"525","article-title":"International patterns and trends in thyroid cancer incidence, 1973-2002","volume":"20","author":"B A Kilfoy","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/SLA.0b013e3181b7faf6","article-title":"Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors","volume":"251","author":"J Lee","year":"2010","journal-title":"Ann Surg"},{"issue":"02","key":"ref3","first-page":"250","article-title":"Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors","volume":"22","author":"J Mihailovic","year":"2007","journal-title":"Cancer BiotherRadiopharm"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/jc.2005-1322","article-title":"Survival and death causes in differentiated thyroid carcinoma","volume":"91","author":"C FA Eustatia-Rutten","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1210\/jcem-60-2-376","article-title":"Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients","volume":"60","author":"N A Samaan","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00259-004-1460-x","article-title":"Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma","volume":"31","author":"S Ilgan","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-15-0296","article-title":"Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors","volume":"173","author":"H-J Song","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0360-3016(85)90126-9","article-title":"Chest computed tomography (CT) in patients with micronodular lung metastases of differentiated thyroid carcinoma","volume":"11","author":"J D Piekarski","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"S 01","key":"ref9","first-page":"28S","article-title":"The evolving role of (131)I for the treatment of differentiated thyroid carcinoma","volume":"46","author":"R J Robbins","year":"2005","journal-title":"J Nucl Med"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"B R Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"03","key":"ref11","first-page":"414","article-title":"Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma","volume":"42","author":"T Shiga","year":"2001","journal-title":"J Nucl Med"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/thy.2012.0654","article-title":"Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors","volume":"24","author":"S W Cho","year":"2014","journal-title":"Thyroid"},{"issue":"09","key":"ref13","first-page":"1048","article-title":"Risk factors for nonremission and progression-free survival after I-131 therapy in patients with lung metastasis from differentiated thyroid cancer: a single institute, retrospective analysis in Southern China","volume":"22","author":"P Chen","year":"2016","journal-title":"EndocrPract"},{"issue":"10","key":"ref14","first-page":"1626","article-title":"Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables","volume":"34","author":"D Casara","year":"1993","journal-title":"J Nucl Med"},{"issue":"06","key":"ref15","first-page":"328","article-title":"Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy","volume":"31","author":"E Kalender","year":"2012","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"01","key":"ref16","first-page":"12","article-title":"Lung metastases from differentiated thyroid carcinoma. A 40 years' experience","volume":"48","author":"G Ronga","year":"2004","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jc.2004-1771","article-title":"Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma","volume":"90","author":"T Y Kim","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1089\/thy.2004.14.1091","article-title":"Papillary thyroid carcinomas with lung metastases","volume":"14","author":"J-D Lin","year":"2004","journal-title":"Thyroid"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/cen.12558","article-title":"Lung metastases from differentiated thyroid carcinoma: prognostic factors related to remission and disease-free survival","volume":"82","author":"S Chopra","year":"2015","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1746175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:10:45Z","timestamp":1764069045000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1746175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":19,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,4,30]]},"published-print":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1746175","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}